Antibodies for p53

Manufactured by Cell Signaling Technology

Sourced in United States

Antibodies for p53 from Cell Signaling Technology are specific immunological reagents designed to detect the p53 protein, a key regulator of cell cycle and apoptosis. These antibodies can be used to identify and quantify p53 in various experimental applications.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using antibodies for p53

Molecular Mechanisms of Cytotoxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols

Convallatoxin was obtained from Pfaltz & bauer (Waterbury, CT, USA). Peruvoside was purchased from Research Plus, Inc. (Barnegat, NJ, USA). Strophanthidin, Thiazolyl blue tetrazolium bromide (MTT), Cisplatin, Sodium dichromate (Na₂Cr₂O₇.2H₂O) [Cr(VI)], Triton X-100, DNAse free RNAse and Propidium Iodide were obtained from Sigma Aldrich (St Louis, MO, USA). Antibodies for p53, phospho-p53, CDK4, Cyclin D1, PARP, XIAP, p-62, phospho-Akt (Ser 473), total-Akt, phospho-ERK, total-ERK, pEGFR, EGFR, β-Catenin, Vimentin, Slug and peroxidase-labeled secondary rabbit and mouse antibodies were obtained from Cell Signaling Technology (Denvers, MA, USA). Antibody for Bcl2 was procured from Santa Cruz Biotechnology (Dallas, TX, USA). Bicinchoninic acid and Supersignal West Pico chemiluminescent substrate was purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Kaushik V., Azad N., Yakisich J.S, & Iyer A.K. (2017). Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers. Cell Death Discovery, 3, 17009-.

+ Open protocol

+ Expand

Cytotoxicity and Apoptosis Assays for Valproic Acid

Check if the same lab product or an alternative is used in the 5 most similar protocols

All chemicals and solvents were purchased from commercial sources and were used as received, unless otherwise noted. Valproic acid, β-cyclodextrin, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide; thiazolyl blue), cetyltrimethyl ammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), (3-aminopropyl)triethoxysilane (APTES), 3-iodopropyltrimethoxysilane (IPTMS), benzimidazole, toluene (anhydrous), fluorescein, 2′,7′-dichlorofluorescein diacetate (DCFDA), Hoechst 33258, calcein blue, and propidium iodide (PI) were obtained from Sigma (St. Louis, MO). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin, and streptomycin were obtained from Gibco BRL (Grand Island, NY). Antibodies for P53, caspase-3, and PARP were obtained from Cell Signaling Technology (Danvers, MA). Monoclonal antibodies for Bcl-2 (50E3) and PARP (46D11) were purchased from Santa Cruz Biotech (Santa Cruz, CA). Monoclonal antibody for Bax (ab5714) was from Abcam (Cambridge, UK). Bicinchoninic acid (BCA) protein assay kit and ECL chemiluminescence system were obtained from Pierce (Rockford, IL) and GE Healthcare (Piscataway, NJ), respectively. Annexin V–fluorescein isothiocyanate (FITC) Apoptosis Analysis Kit (AO2001-02P-H) was purchased from Sungene Biotech (Tianjin, China).

Zhang H., Zhang W., Zhou Y., Jiang Y, & Li S. (2017). Dual Functional Mesoporous Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma. Translational Oncology, 10(2), 229-240.

+ Open protocol

+ Expand

p53 Protein Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Organoid cells were lysed in lysis buffer, and protein samples were separated in 10% SDS-polyacrylamide gel. Antibodies for p53 (Cell Signaling Technology) was used. An anti-β-actin antibody was used as the internal control. The ECL detection system (GE Healthcare) was used to detect the signals. Band intensities were measured using ImageJ application.

Nakayama M., Hong C.P., Oshima H., Sakai E., Kim S.J, & Oshima M. (2020). Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature Communications, 11, 2333.

+ Open protocol

+ Expand

Assessing Therapeutic Compounds in Cell Death

Check if the same lab product or an alternative is used in the 5 most similar protocols

Salinomycin, sanglifehrin A (SfA), cyclosporine A (CsA), n-acetyl cysteine (NAC), temozolomide (TMZ) and pyrrolidinedithiocarbamate (PDTC) were purchased from Sigma (St. Louis, MO). Necrostatin-1 (Nec-1) was purchased from Cayman Chemical (Beijing, China). Antibodies against tubulin and Cyp-D were purchased from Santa Cruz Biotech (Santa Cruz, CA), antibodies for p53 (regular and specific sites of phosphorylation) were purchased from Cell Signaling Technology (Danvers, MA).

Qin L.S., Jia P.F., Zhang Z.Q, & Zhang S.M. (2015). ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis. Journal of Experimental & Clinical Cancer Research : CR, 34(1), 57.

+ Open protocol

+ Expand

Molecular Effects of Therapeutic Agents in Pulmonary Hypertension

Check if the same lab product or an alternative is used in the 5 most similar protocols

CX‐5461 was from ApexBio Technology LLC (Houston, TX, USA). Monocrotaline (MCT, #C2401) and Sugen (SU 5416, #S8442) were purchased from Sigma‐Aldrich (St Louis, MO, USA). Pifithrin‐α was purchased from Selleck Chemicals (Houston, TX, USA). Primary antibodies used were as follows: phospho‐UBF1 (S484) (#ab182583, 1:100 for immunohistochemistry), proliferating cell nuclear antigen (PCNA) (#ab18197, 1:500 for immunofluorescence, RRID:AB_444313), α‐smooth muscle actin (α‐SMA, #ab5694, 1:200 for immunohistochemistry, RRID:AB_2223021), CD68 (#ab125212, 1:500 for immunohistochemistry, RRID:AB_10975465), CD4 (#ab203034, 1:400 for immunohistochemistry), CD8 (#ab33786, 1:200 for immunohistochemistry, RRID:AB_726709), and CD31 (#ab182981, 1:1500 for immunohistochemistry) were from Abcam (Cambridge, UK). Antibodies for p53 (#2524, 1:1000 for western blot, RRID:AB_331743) and phospho‐p53 (Ser15) (#9284, 1:1000 for western blot and 1:150 for immunohistochemistry, RRID:AB_331464) were from Cell Signaling (Beverley, MA, USA).

Xu X., Feng H., Dai C., Lu W., Zhang J., Guo X., Yin Q., Wang J., Cui X, & Jiang F. (2021). Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling. British Journal of Pharmacology, 178(7), 1605-1619.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!